Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335552600> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2335552600 abstract "Background: Different gene expression sets have been reported to reproducibly assess the metastatic potential of early stage operable breast tumors. Knowledge of the biology-based components of amalgamated expression scores may provide insight into the relative contributions of the cellular processes involved. We sought to compare a composite metastasis score (cMS) consisting of a previously reported Metastasis Score (MS), that serves essentially as a proliferation index, and the progesterone receptor (PR) with the Oncotype DX® Recurrence Score (RS) in a regional cancer center setting. Methods: We examined sections from 152 blocks collected in the Blumenthal Cancer Center that had Oncotype DX® scores (a commercially available service performed by Genomic Health Inc. (GHI)). The study protocol was approved by the Institutional Review Board of the Blumenthal Cancer Center. ER and PR were initially scored by IHC; HER2 was determined by FISH. RT-PCR multiplex TaqMan assays of a 14-gene Metastasis Score (Tutt et al. (2008)) and a multiplex assay for ER, PR and HER2 (Iverson et al. (2009)) were carried out. A cMS was generated with MS and PR using previously constructed weighting. Risk classification of cMS was based on a single pre-established cut point; GHI recommended cut points were used for categorized Oncotype DX® risk. Correlations were estimated by Pearson9s product-moment correlation coefficient; a goodness-of-fit test was used to determine differences in the categorical proportions. Results: Eighty-nine (59%), 51 (34%), and 12 (8%) of the 152 tumors tested had low, intermediate and high Oncotype DX® Recurrence Scores, respectively. The continuous scores for cMS and RS were correlated (r=0.71). Of the 89 tumors categorized as low risk by RS, 78 (88%) and 11 (12%) were at low and high risk by cMS, respectively; all (12) of the tumors categorized as high risk by RS were high risk by cMS; and of the 51 tumors with intermediate RS, 27 (53%) were categorized as low risk and 24 (47%) as high risk by cMS. Correlations of RT-PCR PR levels with overall RS and cMS scores were 0.70 and 0.71, respectively. The MS had correlations of 0.50 and 0.80 with RS and cMS, respectively. The categorized risk proportions of this patient population differed from those reported by Paik et al. (2004) (p=1.47x10 -7 ). Tumors with HER2 gene amplification by FISH [3/141 (2%)] were under-represented (p=0.016) relative to Paik et al. (2004) [55/715 (8%)]; the proportion of PR negative tumors for Paik et al. [126/668 (19%)] and this study [14/149 (9%)], were also dissimilar (p=0.006). Conclusions: Despite sharing few genes, the continuous scores for cMS and RS show good correlation. The correlation of PR with these two scores suggests the level of this hormone receptor makes a similar significant contribution to both scores in this patient population. MS was more highly correlated to cMS than RS. Distinguishable features of cMS relative to the amalgamated RS include binary categorization of a continuous score and availability and transparency of discrete and combined scores for the endocrine and proliferation components. Under-representation of HER2- amplified tumors suggests exclusion of this patient group from testing. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-07-05." @default.
- W2335552600 created "2016-06-24" @default.
- W2335552600 creator A5002678881 @default.
- W2335552600 creator A5025213784 @default.
- W2335552600 creator A5057631513 @default.
- W2335552600 creator A5058470688 @default.
- W2335552600 creator A5074964557 @default.
- W2335552600 creator A5078882754 @default.
- W2335552600 creator A5091191948 @default.
- W2335552600 date "2010-12-15" @default.
- W2335552600 modified "2023-09-27" @default.
- W2335552600 title "Abstract P4-07-05: Correlation of a Proliferation Index Combined with Progesterone Receptor to Oncotype DX® in Early Stage ER-Positive Breast Cancer" @default.
- W2335552600 doi "https://doi.org/10.1158/0008-5472.sabcs10-p4-07-05" @default.
- W2335552600 hasPublicationYear "2010" @default.
- W2335552600 type Work @default.
- W2335552600 sameAs 2335552600 @default.
- W2335552600 citedByCount "0" @default.
- W2335552600 crossrefType "proceedings-article" @default.
- W2335552600 hasAuthorship W2335552600A5002678881 @default.
- W2335552600 hasAuthorship W2335552600A5025213784 @default.
- W2335552600 hasAuthorship W2335552600A5057631513 @default.
- W2335552600 hasAuthorship W2335552600A5058470688 @default.
- W2335552600 hasAuthorship W2335552600A5074964557 @default.
- W2335552600 hasAuthorship W2335552600A5078882754 @default.
- W2335552600 hasAuthorship W2335552600A5091191948 @default.
- W2335552600 hasConcept C104317684 @default.
- W2335552600 hasConcept C121608353 @default.
- W2335552600 hasConcept C126322002 @default.
- W2335552600 hasConcept C143660080 @default.
- W2335552600 hasConcept C143998085 @default.
- W2335552600 hasConcept C146357865 @default.
- W2335552600 hasConcept C151730666 @default.
- W2335552600 hasConcept C2779013556 @default.
- W2335552600 hasConcept C2781188995 @default.
- W2335552600 hasConcept C29456083 @default.
- W2335552600 hasConcept C48023723 @default.
- W2335552600 hasConcept C530470458 @default.
- W2335552600 hasConcept C54355233 @default.
- W2335552600 hasConcept C60644358 @default.
- W2335552600 hasConcept C71924100 @default.
- W2335552600 hasConcept C84606932 @default.
- W2335552600 hasConcept C86803240 @default.
- W2335552600 hasConcept C98717036 @default.
- W2335552600 hasConceptScore W2335552600C104317684 @default.
- W2335552600 hasConceptScore W2335552600C121608353 @default.
- W2335552600 hasConceptScore W2335552600C126322002 @default.
- W2335552600 hasConceptScore W2335552600C143660080 @default.
- W2335552600 hasConceptScore W2335552600C143998085 @default.
- W2335552600 hasConceptScore W2335552600C146357865 @default.
- W2335552600 hasConceptScore W2335552600C151730666 @default.
- W2335552600 hasConceptScore W2335552600C2779013556 @default.
- W2335552600 hasConceptScore W2335552600C2781188995 @default.
- W2335552600 hasConceptScore W2335552600C29456083 @default.
- W2335552600 hasConceptScore W2335552600C48023723 @default.
- W2335552600 hasConceptScore W2335552600C530470458 @default.
- W2335552600 hasConceptScore W2335552600C54355233 @default.
- W2335552600 hasConceptScore W2335552600C60644358 @default.
- W2335552600 hasConceptScore W2335552600C71924100 @default.
- W2335552600 hasConceptScore W2335552600C84606932 @default.
- W2335552600 hasConceptScore W2335552600C86803240 @default.
- W2335552600 hasConceptScore W2335552600C98717036 @default.
- W2335552600 hasLocation W23355526001 @default.
- W2335552600 hasOpenAccess W2335552600 @default.
- W2335552600 hasPrimaryLocation W23355526001 @default.
- W2335552600 hasRelatedWork W1547258662 @default.
- W2335552600 hasRelatedWork W1977799636 @default.
- W2335552600 hasRelatedWork W1980244156 @default.
- W2335552600 hasRelatedWork W1995470900 @default.
- W2335552600 hasRelatedWork W2043450349 @default.
- W2335552600 hasRelatedWork W2300434311 @default.
- W2335552600 hasRelatedWork W2396181567 @default.
- W2335552600 hasRelatedWork W2560534809 @default.
- W2335552600 hasRelatedWork W2789283214 @default.
- W2335552600 hasRelatedWork W2789290256 @default.
- W2335552600 hasRelatedWork W2790947129 @default.
- W2335552600 hasRelatedWork W2944350173 @default.
- W2335552600 hasRelatedWork W2944378414 @default.
- W2335552600 hasRelatedWork W2969536864 @default.
- W2335552600 hasRelatedWork W3000340360 @default.
- W2335552600 hasRelatedWork W3006087019 @default.
- W2335552600 hasRelatedWork W3013568571 @default.
- W2335552600 hasRelatedWork W3132703487 @default.
- W2335552600 hasRelatedWork W3175850439 @default.
- W2335552600 hasRelatedWork W3213008073 @default.
- W2335552600 isParatext "false" @default.
- W2335552600 isRetracted "false" @default.
- W2335552600 magId "2335552600" @default.
- W2335552600 workType "article" @default.